Evidence map›Paper›PMID 36609671›Full record

ArticleHepatology international2023

Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study.

Renguo Guan, Jie Mei, Shaohua Li, Wenping Lin, Min Deng, Wei Wei, Rongping Guo

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Hepatology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Renguo Guan *Department of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, China.ORCID 0000-0002-9487-7369
Jie Mei *Department of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, China.
Shaohua Li *Department of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, China.
Wenping LinDepartment of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, China.
Min DengDepartment of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, China.
Wei WeiDepartment of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, China. weiwei@sysucc.org.cn.
Rongping GuoDepartment of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, China. guorp@sysucc.org.cn.ORCID 0000-0003-2799-3463

Funding

National Natural Science Foundation of China No. 81871985National Natural Science Foundation of China No. 82172579Natural Science Foundation of Guangdong Province No. 2017A030310203Natural Science Foundation of Guangdong Province No. 2018A0303130098
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansImmune Checkpoint InhibitorsPhenylurea CompoundsPyridinesQuinolinesImmune Checkpoint InhibitorslenvatinibPhenylurea CompoundsPyridinesQuinolinesregorafenib

Identifiers

PMID36609671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.